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KAL1 is implicated in 5% of Kallmann syndrome cases, a disorder which genotypically overlaps with
septo-optic dysplasia (SOD). To date, a reporter-based assay to assess the functional consequences of
KAL1 mutations is lacking. We aimed to develop a luciferase assay for novel application to functional
assessment of rare KAL1 mutations detected in a screen of 422 patients with SOD.
Quantitative analysis was performed using L6-myoblasts stably expressing FGFR1, transfected with a
luciferase-reporter vector containing elements of the FGF-responsive osteocalcin promoter.
The two variants assayed [p.K185N, p.P291T], were detected in three females with SOD (presenting
with optic nerve hypoplasia, midline and pituitary defects). Our novel assay revealed signiﬁcant de-
creases in transcriptional activity [p.K185N: 21% (p < 0.01); p.P291T: 40% (p < 0.001)].
Our luciferase-reporter assay, developed for assessment of KAL1 mutations, determined that two
variants in females with hypopituitarism/SOD are loss-of-function; demonstrating that this assay is
suitable for quantitative assessment of mutations in this gene.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Septo-optic dysplasia (SOD) is a rare, highly heterogeneous
disorder (incidence 1:10,000e1:20,000 live-births) (Patel et al.
2006). The diagnosis is based on the presence of at least two ofalth 30 Guilford St London,
.
ork.
r Ireland Ltd. This is an open accesthe following: i) midline defects such as absent septum pellucidum
or agenesis of the corpus callosum, ii) optic nerve hypoplasia or iii)
anterior pituitary hypoplasia with/without anterior pituitary hor-
mone deﬁciencies (Kelberman and Dattani, 2007; Webb and
Dattani, 2010). The condition is part of a wider spectrum of disor-
ders associatedwithmidline defects of the forebrain and congenital
hypopituitarism with phenotypes ranging from cleft palate and
SOD, to holoprosencephaly (HPE) and incompatibility with life.
SOD generally occurs sporadically but environmental, epige-
netic and genetic factors are implicated in its aetiology. These
include mutations in transcription factors that play critical roles ins article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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SOX3, and OTX2 (McCabe et al. 2011a). Recently, the scope of po-
tential genetic candidates has widened with the discovery of mu-
tations/variations in genes classically involved in Kallmann
syndrome (KS; anosmia/hyposmia associated with hypogonado-
trophic hypogonadism) in patients with SOD. These include Fibro-
blast Growth Factor Receptor 1 (FGFR1), ligand FGF8 and PROKR2
(McCabe et al. 2011b, 2013; Raivio et al. 2012), all implicated in the
maturation of gonadotrophin releasing hormone (GnRH) neurons
and/or their migration from the olfactory placode to the ventral
forebrain (Pitteloud et al. 2007; Falardeau et al. 2008). However,
consistent with the overlap in genotypes is the occasional overlap
in phenotypes with the SOD spectrum including cleft lip/palate,
synkinesia and sensorineural hearing loss among others (Jansen
et al. 2000; Massin et al. 2003; Trarbach et al. 2005; Versiani
et al. 2007).
The ﬁrst gene implicated in KS was KAL1, which encodes
anosmin-1, a large 680 amino acid protein consisting of a whey
acidic protein domain, followed by four tandem ﬁbronectin (FnIII)
repeats, which is essential for GnRH neuronal migration. Expres-
sion in many species is not well characterised, but it is known to be
ubiquitously expressed during development and into adulthood in
marsupials (Hu et al. 2011). KAL1 localises to Xp.22.3 in humans and
because of this, more males than females were previously screened
for mutations in KAL1 (S€oderlund et al. 2002). Recently however,
female KS patients have also tested positive for mutations in KAL1
(Shaw et al. 2011) and this may be due to the location of the gene
within the pseudoautosomal region of the X-chromosome, where it
may escape X-inactivation (Shaw et al. 2011).
Our previous work identifying mutations/variations in FGFR1,
FGF8 and PROKR2 in large cohorts of patients with congenital hy-
popituitarism and associated phenotypes including SOD (McCabe
et al. 2011b, 2013; Raivio et al. 2012; McCabe et al. 2013) was
aided by animal models and functional assays. Frustrating efforts to
analyse KAL1 variants, a gene implicated in 5% of KS cases, is the
lack of a suitable animal model (this gene has not been detected in
mice) or a luciferase-reporter assay.
We aimed to screen our original cohort of 422 patients with
SOD/congenital hypopituitarism, and develop a luciferase-reporter
assay for novel functional assessment of detected KAL1 variants,
using a reporter driven by an FGF-responsive osteocalcin promoter
(Kim et al. 2003). The promoter is stimulated by the Protein Kinase
C pathway which is induced upon the interaction of FGF2 ligand
with FGFR1 (Kim et al. 2003). Anosmin-1 is known to enhance
activity particularly in the presence of heparan sulphate (HS), and
we hypothesised that these interactions would be measurable, and
any changes in function due to mutated anosmin-1 discernible
(Pitteloud et al. 2007; Falardeau et al. 2008; Hu et al. 2009). In order
to gain insight into a role for KAL1 in the aetiology of congenital
hypopituitarism, we also investigated by expression analysis, a role
for this gene in human embryonic hypothalamo-pituitary
development.
2. Materials and methods
2.1. Patients
422 patients had previously been recruited from national
(n ¼ 325) and international (n ¼ 97) centres between 1998 and
2010. All had midline defects, either SOD and its variants (n ¼ 375,
89%) or HPE and midline clefts (n ¼ 47, 11%) and had previously
screened negative for other KS and SOD genes including FGF8,
FGFR1, PROKR2, PROK2, CHD7, WDR11, NELF, SOX3, SHH and HESX1.
Ethical committee approval was granted by the UCL Institute of
Child Health/Great Ormond Street Hospital for Children JointResearch Ethics Committee (London, UK) and written informed
consent was obtained from the patients and/or parents.
2.2. Mutation/variation analysis
The entire coding region of human KAL1 (NM_000216) was
ampliﬁed by PCR [35 cycles (details/conditions provided in
Table 1)]. Ampliﬁed DNA was sequenced using BigDye v1.1
sequencing chemistry (Applied Biosystems) and analysed on a
3730X1 DNA Analyzer (Applied Biosystems/Hitachi, Japan). Varia-
tions were compared for conservation across multiple species,
screened across 480 ethnically-matched controls and cross-
checked against the dbSNP, Exome Sequencing Project (ESP), 1000
genomes and Aggregation Consortium (ExAC; >61,000 genomes)
databases.
2.3. Protein-prediction modelling of KAL1 variants
The human anosmin-1 sequence (Uniprot AC: P23352; ID:
KALM_HUMAN) was used to search the Protein Data Bank (Berman
et al. 2000) using PSI-BLAST (Altschul et al. 1997) with default pa-
rameters. The top hit reported by the PSI-BLAST run was the solu-
tion structure of the extracellular matrix protein anosmin-1 (PDB
ID: 1ZLG) (Hu et al. 2005) with a 99% identity between the se-
quences. This solution structure of the recombinant protein was
determined by X-ray scattering and analytical ultracentrifugation,
and thus the PDB ﬁle only contained alpha-carbon coordinates. In
order to generate the main-chain and side-chain coordinates, the
program MODELLER (Sali and Blundell, 1993) was used with in-
termediate reﬁnement. Subsequently, side-chain packing was re-
optimised using SCWRL4 (Krivov et al. 2009). Detected variations
were modelled using the molecular graphics program Molecular
Operating Environment (MOE, 2012) 2012.10; which was also used
to analyse the model and generate images.
2.4. Functional studies
2.4.1. Constructs and site-directed mutagenesis
Full length wild-type (wt) human KAL1 had previously been
cloned into the pEGFP-N1 expression vector, (BD Biosciences
Clontech), which, in the presence of a mutated KAL1 stop codon,
expresses anosmin-1 conjugated to GFP at the C-terminal (Hu et al.
2009). Detected mutations/variations were introduced using the
QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) ac-
cording to manufacturer's directions; success of mutagenesis was
conﬁrmed by direct sequencing as detailed earlier.
2.4.2. Cell culture
Cos7 cells (American Type Culture Collection, ATCC, Manassas,
VA, USA) and FGFR1-stably transfected L6-myoblast cells (kindly
provided by Professor Erhard Hohenester, Imperial College, London,
UK) were maintained in a humidiﬁed CO2 (5%) incubator at 37 C in
Dulbecco's Minimum Essential Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA).
Media was replaced at 2-day intervals.
2.4.3. Transfection of constructs for qualitative analysis
Cos7 cells in 6-well plates were transiently transfected with
equal amounts (1 mg) of wt and mutant/variant pEGFP-N1-KAL1
constructs. Empty pEGFP-N1 (1 mg) vector served as the control.
Transfection reagent FuGene6 (Roche) was employed at a 3:1 ratio
with the total mass of DNA (1 mg) transfected. Cells were then left
for 48 h in the presence of 10% fetal bovine serum prior to ﬁxation
for immunocytochemistry or lysis for western blot analysis. Cul-
tures and treatments were performed three times in triplicate.
Table 1
PCR-speciﬁc conditions used for KAL1 ampliﬁcation.
KAL1 exon Forward primer (50-30) Reverse primer (50-30) Product size (bp) Annealing temp (oC) MgCl2þ (mM) DMSO þ/
1 GTTGCCTGGTCCTCAGCAGT AACTTTGCGAGCCCAGGCTG 392 62 1.5 þ
2 TCATTGGAAGGGAAGGACAG ATTGGTGGAAACTGGGCATA 322 58 1.5 þ/
3 TTTGGTCCGCGTTCTGTAAT TGACCCCACGTAAGCATAGTC 325 58 1.5 e
4 AAAGGTTTGGTGGGGAAAAA CTGCCCCATGTCGAGTTAAT 526 58 1.5 e
5 AGGAGCAAATAGCTGAACTG CGAGCACATTCGTTTGTATC 564 52 1.5 e
6 GCATTGGCTGATGGGTTAGT AAAACAGCAAAGCCACCTGT 352 58 1.5 e
7 CCCCGTTTTCAGCTTTTCTA GAAATGAATGGGAGGGAAGC 462 58 1.5 e
8 GCACCTGGCCTGAAGTTTAT CTCCATTGTGCCTTGTTGTG 404 57 1.5 e
9 TGTGTTGTTCTCGCTGGAAG CCTTAGTATTGATACTGTGGCTTGAC 363 58 1.5 e
10 ATCTCACCTCCTTTGGCTCA CCATTCTGCTTTCCACTTCC 386 57 1.5 e
11 GGGAGTGTTTCACAATTGTCA AGGCACTTTTGGTTTTCACG 469 58 1.5 e
12 GCCGCTGAAAATTCCTACAA GCAAAAATAAGACTCAATAGTGCAG 424 57 1.5 þ/
13 AGAGAACCCCCACAAATGA TTCCCTATCTCATAGAAACCTGT 438 58 1.5 þ/
14 CAGGGTCTCGTGCTTTTTCT TGGAAGTGTGCATGTCTCGT 231 57 1.5 þ
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We sought to exploit the known interactions between anosmin-
1, heparin and the FGFR1 signalling pathway in a similar manner to
that published for FGF ligands (Pitteloud et al. 2007; Falardeau et al.
2008; Hu et al. 2009), in L6-myoblast cells. In contrast to Cos7 cells,
L6-myoblasts have low levels of endogenous FGF ligands and re-
ceptors (Pitteloud et al. 2007). Asmentioned above, wewere able to
obtain L6-myoblasts which stably express FGFR1.
Cells were plated at 1  105/well in a 6 well plate. One day
before transfection, media was replaced with serum-free medium.
Transfection was again conducted with FuGene6 at a 3:1 ratio with
DNA (total 2.128 mg) with empty vector or wt/variant KAL1 con-
structs (1 mg, as above), in addition to luciferase reporter p6xOSE2-
Luc (1 mg) which contains 6 tandem repeats of the osteoblast-
speciﬁc core binding sequences of the FGF responsive osteocalcin
promoter cloned into the XmaI site of the pGL2 promoter reporter
vector [Promega; kindly produced and donated by Dr Hyun-Mo
Ryoo, School of Dentistry, Seoul National University, South Korea
(Kim et al. 2003; Park et al. 2010)]. The efﬁciency of transfection
was standardised to a constitutively active pRL-SV40 Renilla lucif-
erase (Promega) internal control (128 ng). Cells were then incu-
bated for 48 h in the absence of serum. Halfway through this period,
cells were treated with 1 nM recombinant human (rh)-FGF2
(PeproTech) with or without 1 mg/ml porcine intestinal mucosa
heparin [a type of heparan sulphate (HS); Sigma]. At the end of the
culture, cells were lysed, processed and assayed for luciferase ac-
tivity using the Dual-Luciferase Reporter Assay System (Promega)
and read on the FluorStar Optima (BMG technologies). Schematic
diagrams of expression and reporter vectors used herein are pro-
vided in Supplementary Fig. 1.
2.5. Immunocytochemistry
Immunocytochemistry was conducted on paraformaldehyde-
ﬁxed Cos7 cells 2 days after wt/variant anosmin-1 transfection to
assess localisation. Given that anosmin-1 was conjugated to GFP, no
direct immunocytochemical procedures were required to detect
the protein. However, in order to assess the localisation of the
protein with respect to the cell nuclei and cell membranes, we
probed b-catenin of the adherens junction [mouse anti-b-catenin
primary antibody (0.5 mg/ml; BD Transduction Laboratories) and
goat anti-mouse, Alexa-546 conjugated secondary antibody
(1:400; Molecular Probes)] and used nuclear-counterstain 40,6-
diamidino-2-phenylindole dihydrochloride (DAPI; Molecular
Probes). Experiments were conducted in duplicates with multiple,
representative photographs acquired (n ¼ 3) by epiﬂuorescence
microscopy (Nikon Eclipse TE 200).2.6. Western blot analysis
Equivalent amounts of protein extracted from Cos7 cells were
separated by SDS-PAGE on 10% gels and transferred onto Amer-
sham Hybond-P, poly (vinylidene diﬂuoride) membranes (GE
Healthcare) for Western blot analysis. GFP-anosmin-1 was probed
with chick anti-GFP primary antibody (AbCam; ab13970; 1:5000)
and goat-anti chicken IgY, HRP-conjugated secondary antibody
(AbCam: ab6877; 1:5000). Bands were visualised using ECL
(Western blotting detection reagents) chemicals (GE Healthcare)
and Amersham Hyperﬁlm (GE Healthcare) which had been
exposed to the membranes.
2.7. In situ hybridisation
In order to gain some insight into a potential role of KAL1 in
hypothalamo-pituitary development, we obtained human embryos
at 6 and 8 weeks of gestation from the Human Developmental
Biology Resource (University College London Institute of Child
Health, London, UK). An ~810bp fragment was cloned from the full
length wt pEGFP-N1-KAL1 construct and inserted into pBluescript.
In situ hybridisation was then conducted on parafﬁn embedded
sections as previously described (Gaston-Massuet et al. 2008).
2.8. Statistical analyses
Culture experiments were tested for normal distribution and
equal variance before being compared to controls by ANOVA, fol-
lowed by Student NewmaneKeuls test to determine where any
differences lay. p < 0.05 values were considered statistically sig-
niﬁcant. Analyses were performed using SigmaStat version 3.5
(Systat Software, Inc., San Jose, CA) and data have been expressed as
mean ± SD.
3. Results
3.1. Patients and phenotypes
We detected two heterozygous KAL1 sequence variants occur-
ring at conserved alleles in three females from two unrelated
families with SOD (Fig. 1); c.555G > C (p.K185N) identiﬁed in a
patient with bilateral optic nerve hypoplasia, hypopituitarism and
an ectopic posterior pituitary on magnetic resonance imaging
(MRI), and c.871C > A (p.P291T), detected in two sisters with
bilateral optic nerve hypoplasia, anterior pituitary hypoplasia and a
cavum septum pellucidum. In both cases their mothers were un-
affected heterozygous carriers. None of these patients harboured
Fig. 1. Electropherogram representation of two heterozygous variants found in KAL1 and their conservation across multiple species. Variant c.555G > C, p.K185N (A; mutant
sequence on bottom indicated by arrow) was detected in a female patient with septo-optic dysplasia, characterised by optic nerve and pituitary defects. The variant was highly
conserved from mammals to zebraﬁsh (B). Variant c.871C > A, p.P291T (C; mutant sequence on bottom indicated by arrow) was detected in two sisters with septo-optic dysplasia
characterised by optic nerve and pituitary defects, as well as cavum septum pellucidum. The variant was highly conserved across mammals (D).
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harboured either variant. However, despite their high interspecies
conservation, both variants appear rarely (<1%) in the dbSNP, ESP
and ExAC databases: p.K185N; 0.01%e0.07% in Caucasians, 0.0%e
0.06% African Americans and p.P291T; 0.0%e0.09% in Caucasians,
0.0% African Americans. The sisters presenting the p.P291T variant
were of African/Caucasian descent, and both variants have been
predicted to be functionally deleterious by two separate algorithms
(SIFT and Polyphen II). p.K185N has also been identiﬁed previously
in a female with GnRH deﬁciency (Shaw et al. 2011).
3.1.1. Patient 1 (c.555 G > C, p.K185N)
This female patient was the ﬁrst child of unrelated Caucasian
parents, born at term by forceps delivery, with a birth weight of
3.76 kg (þ0.31SDS). She developed hypothermia and persisting
hypoglycaemia on day 1 of life. A baseline screen at the time of
hypoglycaemia (glucose 1.4 mmol/l) showed an undetectable
cortisol (<0.9 mg/l) with an insufﬁcient rise in adenocortico-
trophic hormone (ACTH) of 5 ng/l (range 5e50 ng/l) suggesting
ACTH deﬁciency, free T4 of 1 ng/dl (range 0.69e1.69 ng/dl) and a
thyroid stimulating hormone (TSH) of 4.5 mU/l. Subsequent in-
vestigations revealed a free T4 in the low normal range of 0.89 ng/
dl (range 0.69e1.69 ng/dl) suggesting evolving TSH deﬁciency,
and the patient was treated with hydrocortisone and thyroxine. A
pituitary MRI performed in the neonatal period revealed an
ectopic posterior pituitary and bilateral optic nerve hypoplasia. At
the age of 18 months her height was 81 cm (þ0.19SDS), with a
midparental height of 0.22SDS, and her weight was 13 kg
(þ1.58SDS). Testing with glucagon stimulation conﬁrmed growth
hormone (GH) (peak GH: 0.6 mg/l) and cortisol (basal and peak
cortisol <0.9 mg/l) deﬁciencies; treatment with rhGH was then
commenced. Visual acuity on the left was 6/6 with no perception
of light on the right. She had normal development and no asso-
ciated hearing or other systemic problems. By the age of 11.5
years there was no sign of puberty; she had a poor response to
GnRH stimulation (peak luteinising hormone 0.6U/l, follicle
stimulating hormone 2.7U/l) and puberty was induced at 11.9
years.
3.1.2. Patients 2.1 and 2.2 (c.871C > A, p.P291T)
These siblings were born to unrelated parents of African andCaucasian origin. The eldest sibling was born at term with a birth
weight of 2.32 kg (2.85SDS). She had an uncomplicated neonatal
period and ﬁrst presented at the age of 6 months for assessment of
nystagmus (left sided) and esotropia (right side). At that time she
had a height of 1.34SDS with a weight of þ0.23SDS and the MRI
showed bilateral optic nerve hypoplasia, with a hypoplastic optic
chiasm and a cavum septum pellucidum. Baseline investigations
revealed a cortisol of 9.78 mg/dl, free T4 1.24 ng/dl (range
0.69e1.47 ng/dl) and TSH 3.3 mU/l (0.4e4.5 mU/l). She did not have
dynamic testing of the hypothalamo-pituitary axis and received no
hormonal replacements. She has visual impairment with no func-
tional vision in the left eye and visual acuity 6/18 in the right eye.
The younger sibling was born at 37 weeks of gestation with a
birth weight of þ1.84SDS. She presented at the age of ten months
with bilateral vertical nystagmus and inability to ﬁx and follow. She
had a height of 1.20SDS with a weight of 0.1SDS and MRI revealed
bilateral optic nerve hypoplasia with a hypoplastic optic chiasm,
thinning of the corpus callosum, and anterior pituitary hypoplasia
with an absent posterior pituitary. She had a low peak GH to
arginine stimulation (2.5 mg/l) and an adequate peak cortisol to
synacthen (34 mg/dl), with normal thyroid function [free T41.24 ng/
dl (range 0.69e1.47 ng/dl), TSH 1.4 mU/l (range 0.40e4.5 mU/l)].
She started treatment with rhGH and progressed well thereafter.
There was no history of SOD in the family but their ﬁrst cousin on
mother's side has Moebius syndrome. None of the siblings had
hearing defects or renal problems.
3.2. Protein-prediction modelling
To ascertain whether these rare variants detected in females
with severe phenotypes would be ideal candidates for optimising a
new functional assay for KAL1 assessment, we conducted protein-
prediction modelling. The p.K185N variant occurs in the loop be-
tween the WAP and ﬁrst FnIII (FnIII.1) domains (Fig. 2). Since
anosmin-1 seems to interact with FGFR1 within these domains (Hu
et al. 2009), it is possible that the p.K185N variant affects this
interaction. Alternatively, since the interaction of heparan sulfate,
present in the extracellular matrix (ECM), is important for the
localisation and binding of anosmin-1 to the ECM (Hu et al. 2004),
the loss of the positively charged lysine at p.K185 may have im-
plications for negatively charged HS binding.
Fig. 2. Ribbon representation of the six domain solution structure model of anosmin-1, N-terminal on left. Beta-strand ribbons in yellow, helix ribbon in red and turns in blue. The
domains are labelled as follows: CR, cysteine rich region; WAP, whey acidic protein-like, FnIII, ﬁbronectin type III. The p.K185N, located between WAP and FnIII.1, and p.P291T,
located between FnIII.1 and FnIII.2, variations are indicated in space ﬁlling representation for the N and T residues. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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FnIII domain (FNIII.2) (Fig. 2). The conformationally constrained
proline being mutated to a more ﬂexible threonine may alter the
spatial disposition of the FnIII.1 and FnIII.2 domains. Alternatively,
the p.P291T variation is close to a predicted HS proteoglycan
binding site (S278eS293) on beta-strand G of FnIII.1 (Robertson
et al. 2001) and may thus disrupt localisation and binding to the
ECM. Subsequently, we decided that these variants were good
candidates to continue functional assessment thereof.
3.3. Qualitative functional analysis
Given the predicted changes in mutant protein function and
particularly in conformation for the p.P291T variant, we assessed
changes in their localisation relative to wt protein in Cos7 cells,
using b-catenin as a cell-surface marker. Cells which had been
transfected with wt anosmin-1-GFP, demonstrated co-localisation
with b-catenin at the cell surface (Fig. 3A). Cellular localisation
for the p.K185N-GFP variant appeared similar to wt (Fig. 3B). While
p.P291T-GFP also appeared to be secreted from the cells, there was
occasional evidence of its retention within the cytoplasm
(Fig. 3C,D), an effect which was not observed with either wt or the
p.K185N variant protein. Cellular retention of the p.P291T-GFP
construct appeared to be qualitatively conﬁrmed by Western blot
analysis (Fig. 3E), however media extracts, but not cell lysates,
demonstrated cleavage of the anosmin-1 product as previously
described in the presence of serum (Ruvarli et al. 1996; Robertson
et al. 2001; Hu et al. 2004). While this cleavage occurs after
FnIII.2 and so downstream of our mutations, we considered it
preferable to maintain a fully intact protein for quantitative func-
tional analyses. For this reason serum was omitted from the media
following transfection of the L6-myoblasts.
3.4. Quantitative functional analysis
Given the predicted deleterious effects of these detectedvariants and the occasional retention of the p.P291T variant, we
proceeded with quantitative analyses of these changes. As previ-
ously described, our assay was designed to exploit the interaction
of anosmin-1 with FGFR signalling (Fig. 4A). L6-myoblasts stably
expressing FGFR1 that had been transfected with the luciferase
reporter only, were dose responsive to rhFGF2 (Fig. 4B). wt KAL1
treatment induced high luciferase readings (Fig. 4C), which were
signiﬁcantly greater than cells treated with either the p.K185N
variant vector (21% reduction; p < 0.01) or the p.P291T variant (40%
reduction; p < 0.001). The degree of functional impairment was
also signiﬁcantly different between the two variant constructs
(p < 0.05).
Treatment with heparin in addition to rhFGF2 (Fig. 4D), abol-
ished the difference in functional activity observed betweenwt and
the p.K185N variation, but the p.P291T variant was still signiﬁcantly
compromised functionally compared to wt (p < 0.05) and p.K185N
(p < 0.01).3.5. Expression of KAL1 in the developing human embryo
Given that we had identiﬁed functionally deleterious KAL1
variants in vitro in three females with septo-optic dysplasia asso-
ciated with pituitary phenotypes, we investigated a potential role
for KAL1 in human embryonic hypothalamo-pituitary develop-
ment. KAL1 gene expression at 6 weeks gestation (Carnegie stage
16) was detected in the dorsal aspect of the primordial anterior
pituitary gland (Rathke's pouch) (Fig. 5A) as well as in the devel-
oping neural tube and dorsal aspects of the developing otic vesicles
(Fig. 5B, C). By 8 weeks gestation (Carnegie stage 23), KAL1 was
observed at lower levels but restricted to the sulcus of the ven-
tricular zone of the 3rd ventricle where neural progenitors reside in
the hypothalamic region, and also in the basal ganglia (Fig. 5D, B0,
C0). No pituitary expression was observed at this stage. However,
expression was also seen in the inner ear canals that will form the
cochlea (Fig. 5E).
Fig. 3. Qualitative functional analysis of anosmin-1 protein localisation/expression in transfected Cos7 cells. A-D, expression constructs encoding wt KAL1 (A) or variant p.K185N or
p.P291T proteins (B and C/D (low magniﬁcation) respectively) conjugated to GFP were transfected into Cos7 cells. Two days after transfection, cells were ﬁxed for immunocyto-
chemical analysis or lysed for protein extraction prior to western blot analysis (E). For the immunocytochemical stains, anosmin-1 (green), was co-localised with b-catenin of the
adherens junction (red) to highlight cellular membranes. Cell nuclei were highlighted with DAPI (blue). Secreted anosmin-1 is indicated by arrows and retained protein is indicated
by asterisks. E, western blot analysis was conducted on protein extracted from cell lysates or culture media. Bands corresponding to anosmin-1 are indicated by arrows. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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We have successfully applied a luciferase-reporter assay for
novel quantitative assessment of rare variants/mutations in KAL1.
Given that the two variants identiﬁed were rare, occurred at
conserved residues, and were predicted to be deleterious in silico,
we assessed their functional impact with our assay. The two vari-
ants detected herein in three females with SOD, p.K185N and
p.P291T, were indeed deemed to be loss-of-function changes.
To investigate the variants, we used L6-myoblasts. This cell-line
has been used for the study of FGFR1 signalling due to the intrin-
sically low to non-existent levels of expression of endogenous FGF
ligands and receptors (Pitteloud et al. 2007). The cells used in this
study had previously been stably-transfected with FGFR1 (Hu et al.
2009). Both FGF ligands and receptors bind to HS and heparin (a
heavily sulfated form of which is present in connective tissue mast
cells); these cell surface proteoglycans are essential for the for-
mation of the FGF-FGFR signalling complex (Mohammadi et al.
2005; Hu et al. 2009). However, other co-factors such as
anosmin-1 are also known to interact with or regulate this
pathway. This was postulated initially through the induction of
neurite outgrowth and cytoskeletal rearrangements in a human
embryonic gonadotrophin-releasing hormone (GnRH)/olfactory
neuroblast (FNC-B4) cell-line via FGFR-dependent mechanisms,following recombinant anosmin-1 treatment (Gonzalez-Martínez
et al. 2004). Hu et al. (2009) subsequently conﬁrmed this as a
direct interaction of anosmin-1 with FGFR1-FGF2; enhanced by HS/
heparin. The suitability of our model for this study was demon-
strated through the dose response to rhFGF2 in luciferase reporter
activity, and through discernible differences in receptor activity
between wt and variant KAL1 transfected cells.
The p.K185 residue lies between the WAP and ﬁrst FnIII binding
domains (Gonzalez-Martínez et al. 2004). Although protein
modelling predicted disrupted binding between the p.K185N
variant and HS, treatment with heparin restored function in the
presence of the variation. Potentially, by adding more HS to that
already present endogenously, we overcame the functional deﬁcit
of the variant, as was also partially observed for p.P291T. Alterna-
tively, our results were consistent with the known enhancement of
interaction between anosmin-1 and FGF-FGFR signalling in the
presence of HS as mentioned above (Hu et al. 2009).
The functional impact of the p.P291T variant was signiﬁcantly
greater than that observed with the p.K185N change (p < 0.05).
Although the variation occurs just after the prime FGFR1/heparan
sulfate-binding domain, it is hypothesised that it may disrupt ﬁnal
protein folding and conformation. Our qualitative studies suggest
that the secretion of the protein may also have been disrupted, as
demonstrated by the occasional retention of p.P291T-anosmin-1
Fig. 4. Quantitative functional analysis of anosmin-1 variants. A, Schematic representation of the FGFR pathway which our luciferase reporter vector (p6xOSE2-Luc) exploits.
Binding of FGF2 ligand to FGFR1 stimulates dimerisation of the receptor and subsequent signalling cascades. These signals are enhanced through anosmin-1 binding to the receptor,
which can be positively mediated by heparan sulfate. B, In order to validate our functional assay, FGFR1-expressing L6-myoblasts were transfected with our luciferase reporter and
then treated with increasing doses of rhFGF2. C and D, FGFR1-expressing L6-myoblasts were then transfected with empty vector (labelled as GFP) or wt or variant KAL1-GFP
conjugated constructs as well as our luciferase reporter and Renilla luciferase internal control. Cells were then treated with rhFGF2 with (D) or without (C) heparin (a type of
heparan sulfate). The left column of each graph labelled ‘cells,’ were untransfected cells, still treated with 1 nM rhFGF2 ± 1 mg/ml heparin. All treatments were done in triplicate,
with cultures repeated three times in total. Data are presented as mean ± SD. ns ¼ not signiﬁcant, * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001. Note that panel A is adapted from Hu
and Bouloux (2011).
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One may then question how the loss-of-function variants
detected herein ﬁt within the broader context of KS and hypopi-
tuitarism/SOD. Our results, and that of a recently published ﬁnding
which detected a missense KAL1 variant in a male with hypopitu-
itarism, support the known overlap in genotypes between KS and
congenital hypopituitarism (McCabe et al. 2011b; Raivio et al. 2012;
Vaaralahti et al. 2012; McCabe et al. 2013; Takagi et al. 2014). Due to
the young age of the sisters with the p.P291T variant, it was not
possible to test for KS associated phenotypes such as anosmia orhypogonadotrophic hypogonadism. The patient with the p.K185N
variant however was non-responsive to GnRH and puberty was
induced. Phenotypic manifestations in females due to mutations in
KAL1 may be possible given its localisation to the X-chromosome
pseudoautosomal region (PAR). While most of the genes along one
of the X-chromosomes are inactivated to ensure dosage compen-
sation or equal gene expression between males and females, those
within the PAR escape this process (Mang and Morris, 2007; Shaw
et al. 2011). This would appear to suggest that during fetal devel-
opment, females would have double the gene dosage of KAL1
Fig. 5. In situ hybridisation analysis of KAL1 expression in the developing human embryo at 6 weeks (Carnegie stage 16) and 8 weeks (Carnegie stage 23) gestation. A, KAL1 mRNA
transcripts were observed transiently in the dorsal aspect of Rathke's pouch (primordial anterior pituitary gland) at 6 weeks (arrowheads). B, Expression was also observed in the
developing neural tube (arrows heads in B and arrow in C). C, Strong localised expression was consistently observed in the dorsal aspect of the developing otic vesicles (OV,
arrowhead). D, At week 8, KAL1 mRNA transcripts were observed in the sulcus of the ventricular zone of the 3rd ventricle where the neural progenitors reside (labelled as 3V,
arrowheads in B0), in the vicinity of the hypothalamus. No expression was detected in the pituitary (asterisk). B0 and C0 are enlarged images from D. C0 shows KAL1mRNA expression
in the basal ganglion (arrowheads). E, KAL1 was also observed in the developing inner ear (IE) that will form the cochlea (arrowheads). Abbreviations: 3V, third ventricle; DNT,
dorsal neural tube; DRG, dorsal root ganglia; IE, inner ear; NT, neural tube; OC, oral cavity; OV, otic vesicle; RP, Rathke's pouch. Scale bars from AeD are 200 mm.
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chromosome is a largely homologous KAL1 pseudogene termed
KALP (del Castillo et al. 1992; Montenegro et al. 2013), which is
expressed in human embryonic stem cell lines. Study into the
function of KALP has not been conducted to the best of our
knowledge, but given the increasing evidence for a functional role
for pseudogenes, a role for KALP could beworth exploring (Poliseno
et al. 2010; Dhahbi et al. 2013; Pink and Carter, 2013).
However, care needs to be taken when interpreting our func-
tional data in the clinical setting, as was recently demonstrated for
PROKR2[p.L173R], where a homozygote was completely unaffected
phenotypically (McCabe et al. 2013). The mothers of the variant-
KAL1 affected girls were unaffected carriers. This may indicate
variable penetrance, but more likely, that other genetic or epige-
netic factors may be implicated (Canto et al. 2009). Sequencing of
other known KS and SOD genes revealed no other mutations;
however given that genetic causes have been implicated in thesedisorders at a low incidence of ~30% and ~1% respectively (Dode
and Hardelin, 2010; Webb and Dattani, 2010), there is a large
pool of contributory genes which have yet to be identiﬁed and
which could be contributing to the phenotypes presented by our
patients. Supporting this notion is the appearance of the variants in
control databases (albeit rarely) and the relatively modest, albeit
signiﬁcant, decrease in mutant protein function detected herein in
girls with such severe SOD and hypopituitarism phenotypes. The
results presented herein are therefore suggestive that KAL1may be
contributing to, rather than being causative of, the phenotypes
observed in our patients.
In studies such as these, knockout or hypomorphic animal
models are often employed alongside functional assays to consol-
idate or disprove the role of candidate genes in a given phenotype.
As mentioned earlier, despite high conservation of Kal1 from
mammal to chick there is no mouse or rat homolog of the gene,
hence difﬁculties in assessing its role in hypothalamo-pituitary
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for KAL1 in this process. Our in situ hybridisation studies in 6-week
(Carnegie stage 16) and 8-week (Carnegie stage 23) human em-
bryos revealed early anterior pituitary and neural tube expression
at 6 weeks, which had become restricted to the 3rd ventricle near
the hypothalamus by 8 weeks. Mature GnRH-secreting neurons are
located here, as are FGF-responsive cells. Kal1a/b knockdown in
zebraﬁsh results in disrupted GnRH and olfactory neuron matura-
tion/migration, consistent with human phenotypes (Whitlock et al.
2005). In chick, concomitant with its expression in olfactory bulbs,
forebrain and hypothalamus, Kal1 has been implicated in neural
crest formation and shown to regulate Bmp5 and Fgf8 (Endo et al.
2012). Erroneous expression of Bmp5 in the chick leads to HPE and
loss of midline structures (Golden et al. 1999), while in humans
FGF8 has been implicated in HPE, SOD and Moebius syndrome, all
in association with hypopituitarism (McCabe et al. 2011b). Notably,
KAL1 has not been shown to regulate FGF8 in humans, but cumu-
latively, evidence from these models support our data which sug-
gest a role for KAL1 in hypothalamo-pituitary development.
Supporting this is the aforementioned paper published recently,
which described hypopituitarism in a male with a missense KAL1
variant (albeit of unknown functional signiﬁcance), who also pre-
sented with combined pituitary hormone deﬁciency, right micro-
phthalmia, renal aplasia, severe developmental delay and mild
hearing impairment (Takagi et al. 2014). Interestingly, the detection
of KAL1 in the developing otic vesicles and inner ear canals in our in
situ hybridisation is consistent with sensorineural deafness being
attributed to KAL1 deletions or missense mutations (Jansen et al.
2000; S€oderlund et al. 2002).
In conclusion, we have developed a luciferase functional assay
for novel application in vitro to demonstrate loss-of-function in rare
variants in X-linked KAL1 in three female patients with SOD and
pituitary abnormalities. This assay may be suitable for assessing
future or currently known variants/mutations in the KAL1 gene. In
the context of KS/SOD, the role of our detected variants in the
presentation of the phenotypes herein is not entirely clear but they
do extend the accepted overlap in genotypes/phenotypes between
these disorders. The genotypic complexity of SOD suggests that
other genes may be contributing to the phenotypes presented by
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